Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133119 | 0.85 | ITGA4 (0.38) | CNR2BRD9GSK3BDYRK1AHDAC3 | |
| SCHEMBL20262397 | 0.82 | ITGA4 (0.36) | TSHRCNR2BRD9GSK3BDYRK1A | |
| SCHEMBL24255779 | 0.81 | GSK3B (0.37) | LMNACNR2BRD9GSK3BDYRK1A | |
| SCHEMBL6133027 | 0.80 | ALDH1A1 (0.46) | LMNAHTT | |
| SCHEMBL2173526 | 0.76 | MAPK1 (0.41) | CNR2NLRP3BRD9GSK3BDYRK1A | |
| SCHEMBL6133587 | 0.76 | ALDH1A1 (0.44) | HTTTSHR | |
| SCHEMBL28862920 | 0.75 | DGAT2 (0.43) | CYP4F2CYP4A11 | |
| SCHEMBL29361179 | 0.74 | CYP4F2 (0.38) | CYP4F2CYP4A11L3MBTL1CYP2C9NLRP3 | |
| SCHEMBL23674639 | 0.74 | CYP4F2 (0.38) | CYP4F2CYP4A11L3MBTL1CYP2C9NLRP3 | |
| SCHEMBL25056521 | 0.74 | LMNA (0.44) | LMNACYP4F2CYP4A11L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004094-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| WO-2004101571-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004094-A1 | Cephem compounds | CEP170, C1S, CEPT1 | LMNA 1933/4885CYP4F2 814/4885CYP4A11 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.